TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03881150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive assessment
Description: Includes evaluation about physical activity, diet, tobacco consumption, overweight/obesity, blood pressure, self-efficacy, and medications. Additionally, levels of lipids and glycaemia will be reviewed from clinical chart.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive assessment
Description: Includes evaluation about physical activity, diet, tobacco consumption, overweight/obesity, blood pressure, self-efficacy, and medications. Additionally, levels of lipids and glycaemia will be reviewed from clinical chart.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Physical activity, diet, smoking, and medication compliance counseling will be provided by the physiotherapist across exercise sessions, using a self-efficacy approach. A booklet was designed in order to support the individual counseling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group education
Description: Group education sessions about physical activity, diet, smoking, and medication compliance (without individual counseling), as actually performed in each center.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise sessions in hybrid program
Description: 10 supervised exercise sessions over 4-6 weeks of aerobic and resistance training will ensue, supervised by a physiotherapist. Exercise sessions are 10 minutes in duration at the beginning of the program, and are progressed to 60 minutes by the end as tolerated.~Intensity of exercise will be moderate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise sessions in standard program
Description: 18-22 supervised exercise sessions are delivered over the 8-12 week program. These sessions include aerobic and resistance training and a similar progression of duration as the experimental group.~Intensity of exercise will be moderate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transition to unsupervised phase
Description: After 4-6 weeks with face-to-face exercise sessions in hybrid program, all patients will be monitored through mobile technology. Delivery methods will include voice calls biweekly, and text messaging three per week through to 10-12 weeks from program initiation. The content will promote physical activity, healthy diet, and medication adherence.
Study: NCT03146533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2/day IV for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8g/m2/day IV for 2 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CART
Description: CD19 CART cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
Study: NCT02301403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: 8 weeks of nicotine patch

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: in-person counseling and quitline counseling
Description: a single brief, in-person counseling session plus a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), for counseling, including the QUITNOW app and the Website

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preparation Nicotine Mini-Lozenges
Description: Nicotine lozenge prior to attempting to quit smoking

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination NRT (nicotine patch + nicotine mini-lozenges)
Description: 26 weeks of combination NRT as part of a quit smoking attempt

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive In-Person Cessation Counseling
Description: three 20-min In-person Cessation Counseling sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Maintenance Counseling Calls
Description: 8 Maintenance-phase smoking cessation counseling sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Adherence Calls
Description: 11 brief, automated calls reminding them to use their medications properly
Study: NCT01221428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells(2\*10/7),one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery(1\*10/7).
Study: NCT02526550

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated chimeric Japanese Encephalitis vaccine
Description: 0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Hepatitis A vaccine
Description: 0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh
Study: NCT01716572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: Intravenous 250 mg of erythromycin, single-dose, 30 minutes before the endoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric lavage
Description: gastric lavage by nasogastric tube with 1 liter of saline before the endoscopy
Study: NCT03580421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ambulatory surgery
Description: total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard surgery
Description: total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
Study: NCT03984058

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle Intervention
Description: A lifestyle intervention program adapted from the Diabetes Prevention Program (DPP). Study participants will start lifestyle intervention on the day of initiating PAP therapy. The 3-month program will be followed: Patient-facing Online Platform: The program will be accessible to study participant via the Web or a Web application available for the Android and iOS devices. Behavioral Weight Loss Goals and Lessons: The program begins with an introductory session that presents the basic goals for the program followed by 12 weekly multimedia lessons. Submission of self-monitoring data: Participants will submit daily weight, caloric intake, and physical activity minutes at least weekly to the study website for 12 weeks. Automated Feedback: In response to the self-monitoring data, participants receive a weekly automated message that compares participants' self-reported values to participants' goals for weekly and overall weight loss, caloric intake, and physical activity minutes.
Study: NCT03448588

Intervention type: DIAGNOSTIC_TEST
Intervention: detection of serum selenium
Description: For this case-control study, no intervention will be administered to participants, only serum sample will be collected for selenium assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: detection of serum selenium
Description: For this case-control study, no intervention will be administered to participants, only serum sample will be collected for selenium assessment
Study: NCT00184145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMDR (Eye Movement Desensitization and Reprocessing)
Description: Psychotherapy which is approved for PTSD.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Description: All participants in the study received exposure therapy som second treatment. Exposure therapy is the therapy of choice for animal phobia.
Study: NCT00482989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI 545
Description: MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks.
Study: NCT00830297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulatard (long-acting insulin)
Description: In group No.1 (study arm 1 (=A)), patients will be treated with long-acting insulin (Insulatard) as soon as the glucose-level before supper surpasses 140 mg/dl. The normoglycemic goal in this group will be from 110 to 120 mg/dl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: In group No.2 (study arm 2 (=B)), patients will be treated conventionally according to the decisions taken by the physicians on the ward. The following suggestions will be brought to the attention of the ward in order to standardize the treatment of the patients in study arm B: 1. Treatment in this group should be initiated if the fasting glucose level surpasses the renal glucose threshold, i.e. 180 mg/dl. 2. As the proposed life-style modifications for the treatment of NODAT1 are not feasible during this very early post-transplant phase, the basis of the conventional therapy will be proposed to be sulfonyl urea drugs (i.e. Gliclazide - Diamicron®, 30 mg, not more than twice daily). 3. Short-acting insulin will be strongly recommended to be used for corrections of capillary blood glucose levels above 250 mg/dl.
Study: NCT03387878

Intervention type: DEVICE
Group type: OTHER
Intervention: Intermittent Catheter
Description: Intermittent urinary catheter for bladder drainage
Study: NCT04220476

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)
Description: Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT. They will undergo tumor Immunogenic-SBRT(I-SBRT) days 1-12 (+/-2 days, to enable inclusion of holidays). During the week preceding day 1, they will undergo simulation and planning for radiotherapy. Each oligometastatic lesion will be treated with I-SBRT every 48 hours. Treatment may be given daily (to keep the total I-SBRT treatment time to ≤ 12 days) and lesions targeted with I-SBRT will thus be alternated each day to accommodate for the 48 hour interval between fractions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5Mg Tab
Description: All patients start standard therapy with oral letrozole (Femara), day 1 of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5Mg Tab
Description: All patients start standard therapy with oral letrozole (Femara), day 1 of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib 125mg
Description: Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib 125mg
Description: Patients randomized to arm 2 will start letrozole alone, and add palbociclib on day 21, after completion of I-SBRT.
Study: NCT02163603

Intervention type: PROCEDURE
Intervention: Pelvic osteotomy
Study: NCT04073524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature-Body-Mind-Community
Description: The Nature-Body-Mind-Community (NBMC) approach has been developed in a pilot project over 2014-2018. The 'Wild man Programme' consists of the following main elements: 1. Nature environments and nature experiences, 2. Mind relaxation and meditation, 3. Body awareness and 4. Fire talks, storytelling and community spirit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual consist of the rehabilitation offered by the hospital or municipality for the specific condition e.i. cancer, diabetes, COPD, anxiety, depression and stress

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Treatment as usual consist of the rehabilitation offered by the hospital or municipality for the specific condition e.i. cancer, diabetes, COPD, anxiety, depression and stress
Study: NCT02267317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eritoran
Description: Pharmacologic inhibitor of TLR4 receptors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eritoran
Description: Pharmacologic inhibitor of TLR4 receptors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D5W
Description: 5% Dextrose Water = Vehicle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D5W
Description: 5% Dextrose Water = Vehicle
Study: NCT03934099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC350189 formulated capsule
Description: Xanthine Oxidase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC350189 formulated capsule
Description: Xanthine Oxidase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC350189 formulated capsule
Description: Xanthine Oxidase Inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT02849730

Intervention type: DEVICE
Intervention: Fentanyl/ropivacaine based Epi-PCA
Description: Fentanyl and ropivacaine was diluted and administered to the patients according to the clinician's determination. The clinician decided dose, infusion rate, bolus dose, lockout time and total amount of drug mixed in the Epi-PCA.

Intervention type: DEVICE
Intervention: Fentanyl/ropivacaine based Epi-PCA
Description: Fentanyl and ropivacaine was diluted and administered to the patients according to the clinician's determination. The clinician decided dose, infusion rate, bolus dose, lockout time and total amount of drug mixed in the Epi-PCA.
Study: NCT03739034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine
Description: Treatment modalities consist of encouraging a plant based, whole food diet, physical activity, stress management, healthy sleep, control of unhealthy habits.
Study: NCT02200809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-guided focal laser ablation
Study: NCT04074161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Dose gradually increased to 2.4 mg administered once weekly for 68 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Administered once weekly for 68 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Dose gradually increased to 3.0 mg administered once daily for 68 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (liraglutide)
Description: Administered once daily for 68 weeks
Study: NCT01689532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg
Description: Sirukumab 100 mg subcutaneous (SC) injection, at Weeks 0, 2, and every 2 weeks through Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg
Description: Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52.
Study: NCT01470170

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal Saline (placebo comparator) was given in equivalent amount of alfentanil dosage in each arm, for double blinded purpose.
Study: NCT01689532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Between sirukumab injections, placebo SC at Weeks 2, 6, and every 4 weeks through Week 52.
Study: NCT03936790

Intervention type: OTHER
Group type: OTHER
Intervention: Ropivacaine
Description: In case of successful spinal anaesthesia, the dose of spinally administered ropivacaine will decrease by 0.375 mg for the next participant.In case of unsuccessful spinal anaesthesia, the dose of spinally administered ropivacaine will increase by 0.375 mg for the next participant.

Intervention type: OTHER
Group type: OTHER
Intervention: Fentanyl
Description: A fix dose of fentanyl (15 mcg) will be co-administered spinally to all participants.
Study: NCT04226768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Haematology Palliative Care (Fast-track) Group
Description: Early and proactive multidisciplinary care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Care
Description: Conventional care and referral as indicated
Study: NCT01470170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal Saline (placebo comparator) was given in equivalent amount of alfentanil dosage in each arm, for double blinded purpose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal Saline (placebo comparator) was given in equivalent amount of alfentanil dosage in each arm, for double blinded purpose.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted controlled infusion
Description: The Propofol dosage was according to the effect site concentration to reach OAAS-3 ( loss of conscious), using Schneider model

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted controlled infusion
Description: The Propofol dosage was according to the effect site concentration to reach OAAS-3 ( loss of conscious), using Schneider model

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Targeted controlled infusion
Description: The Propofol dosage was according to the effect site concentration to reach OAAS-3 ( loss of conscious), using Schneider model

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted controlled infusion
Description: The Propofol dosage was according to the effect site concentration to reach OAAS-3 ( loss of conscious), using Schneider model

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted controlled infusion
Description: The Propofol dosage was according to the effect site concentration to reach OAAS-3 ( loss of conscious), using Schneider model

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The Propofol dosage is according to the effect site concentration to reach OAAS-3 ( loss of conscious), using TCI Schneider model during the whole procedure of bronchoscope

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The Propofol dosage is according to the effect site concentration to reach OAAS-3 ( loss of conscious), using TCI Schneider model during the whole procedure of bronchoscope

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: The Propofol dosage is according to the effect site concentration to reach OAAS-3 ( loss of conscious), using TCI Schneider model during the whole procedure of bronchoscope
Study: NCT05066490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Description: Treadmill training at moderate intensity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Description: Treadmill training at moderate intensity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exersises.
Description: Resistance exercises using the 10 repetition maximum.
Study: NCT02911428

Intervention type: PROCEDURE
Intervention: blood sampling collection
Description: It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.

Intervention type: PROCEDURE
Intervention: blood sampling collection
Description: It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
Study: NCT03396380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D with calcium and clomiphene citrate
Description: 1. Vitamin D ( ossofortin®, EVA PHARMA) 10000 IU twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries ) 1250 mg twice daily which provide elemental calcium 500 mg/tablet for one month before induction of ovulation and both will be continued during the 3 induction cycles in the same regimen.~2. Induction of ovulation by clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily 12 hours apart (total dose 100 mg daily) starting from the third day of menstrual cycle and for five days .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet with calcium and clomiphene citrate
Description: 1. The placebo tablet twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries ) 1250 mg twice daily which provide elemental calcium 500 mg/tablet for one month before induction of ovulation and both will be continued during the 3 induction cycles in the same regimen.~2. induction of ovulation by clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily 12 hours apart (total dose 100 mg daily)starting from the 3rd day of menstrual cycle and for five days
Study: NCT04608695

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian puncture
Description: One side ovary of each patient included in the study, will be punctured 10 times under trans-vaginal ultrasound guidance with 17 gauge ovarian pick up needle, 1 month before the scheduled IVF cycle. Control group will be the other side ovary for each patient. Number of ≥ 14 mm follicle and collected oocytes will be compared.
Study: NCT02841371

Intervention type: RADIATION
Intervention: 99mTc-DTPA
Description: a 99mTc-DTPA renal dynamic imaging measurement as the reference glomerular filtration rate (rGFR).

Intervention type: RADIATION
Intervention: 99mTc-DTPA
Description: a 99mTc-DTPA renal dynamic imaging measurement as the reference glomerular filtration rate (rGFR).
Study: NCT02780882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Study: NCT05223361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Six percent hydroxy ethyl starch 130/0.4
Description: 6% HES 130/0.4 additive to ringer lactate as prime solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer lactate
Description: Ringer lactate as prime solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer lactate
Description: Ringer lactate as prime solution
Study: NCT01478854

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Patients will be treated to a total dose of 60 Gy with a once daily fractionation schedule of 2 Gy per fraction, administered five days per week. All patients will undergo CT simulation with intravenous contrast. In addition they will undergo MRI simulation with both T1 with gadolinium as well as FLAIR sequences. They will be treated in a supine position using an aquaplast mask system for immobilization. CT image data will be reconstructed in approximately 3 mm slice thickness and manually coregistered with T1 post-gadolinium and FLAIR sequence MRI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Temozolomide